Change in number of shares and votes in Immunovia AB (publ)
Comunicato Precedente
Comunicato Successivo
This information is such information that Immunovia AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on 31 January 2025 at 10:00 CET.
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit www.immunovia.com.
This information was brought to you by Cision http://news.cision.com.
https://news.cision.com/immunovia-ab/r/change-in-number-of-shares-and-votes-in-immunovia-ab--publ-,c4098400
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/change-in-number-of-shares-and-votes-in-immunovia-ab-publ-302365196.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom




